2026-05-06 – Press Releases – www.prnewswire.com
PEDMARQSI® is now TGA registered in Australia for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to <18 years of age with localised, non-metastatic, solid tumours TGA registration provides an approved treatment option in an area of significant unmet…
